Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion - A quantitative myocardial contrast echocardiography study

被引:85
作者
Kunichika, H [1 ]
Ben-Yehuda, O [1 ]
Lafitte, S [1 ]
Kunichika, N [1 ]
Peters, B [1 ]
DeMaria, AN [1 ]
机构
[1] Univ Calif San Diego, Div Cardiol, San Diego, CA 92103 USA
关键词
D O I
10.1016/j.jacc.2003.08.040
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES We assessed the effect of glycoprotein IIb/IIIa inhibition (GPI) on microvascular flow after coronary occlusion/reperfusion using quantitative myocardial contrast echocardiography (QMCE). BACKGROUND Platelets may play a major role in the dissociation of epicardial artery recanalization and tissue-level reperfusion, referred to as the "no-reflow phenomenon." Therefore, GPI might improve myocardial reperfusion, distinct from its effects on epicardial patency. METHODS Three-hour occlusion of the left anterior descending coronary artery (LAD) was followed by 3-h reperfusion in 16 open-chest dogs: 8 controls and 8 given a continuous infusion of the GPI tirofiban, starting 45 min before LAD reopening. Perfusion of the LAD bed was quantified by the rate of intensity rise (b) by QMCE; myocardial blood flow (MBF) was assessed by fluorescent microspheres. RESULTS No differences in b or MBF were observed within the risk area between the control and GPI groups at baseline or occlusion. However, b and MBF were higher in GPI dogs than in controls during reperfusion, despite similar epicardial flow (p < 0.05 at 30, 60, and 90 min; p = NS at 180 min). Infarct area size was significantly reduced in GPI dogs compared with non-treated dogs (26.9 +/- 10.5% vs. 49.0 +/- 11.1% of at-risk area, respectively). CONCLUSIONS As demonstrated by QMCE, GPI improves microvascular flow and reduces the infarct area after coronary occlusion/reperfusion, independent of epicardial flow. These data demonstrate the usefulness of QMCE in assessing microvascular flow, provide novel evidence for the role of platelets in the early phase of reperfusion injury, and show that GPI is of value in preserving microvascular perfusion after coronary reperfusion. (C) 2004 by the American College of Cardiology Foundation.
引用
收藏
页码:276 / 283
页数:8
相关论文
共 37 条
[1]   Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention [J].
Anderson, KM ;
Califf, RM ;
Stone, GW ;
Neumann, FJ ;
Montalescot, G ;
Miller, DP ;
Ferguson, JJ ;
Willerson, JT ;
Weisman, HF ;
Topol, EJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (08) :2059-2065
[2]   Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes:: a meta-analysis of all major randomised clinical trials [J].
Boersma, E ;
Harrington, RA ;
Moliterno, DJ ;
White, H ;
Théroux, P ;
Van de Werf, F ;
de Torbal, A ;
Armstrong, PW ;
Wallentin, LC ;
Wilcox, RG ;
Simes, J ;
Califf, RM ;
Topol, EJ ;
Simoons, ML .
LANCET, 2002, 359 (9302) :189-198
[3]   Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction [J].
Brener, SJ ;
Barr, LA ;
Burchenal, JEB ;
Katz, S ;
George, BS ;
Jones, AA ;
Cohen, ED ;
Gainey, PC ;
White, HJ ;
Cheek, HB ;
Moses, JW ;
Moliterno, DJ ;
Effron, MB ;
Topol, EJ .
CIRCULATION, 1998, 98 (08) :734-741
[4]   USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].
CALIFF, RM ;
SHADOFF, N ;
VALETT, N ;
BATES, E ;
GALEANA, A ;
KNOPF, W ;
SHAFTEL, J ;
BENDER, MJ ;
AVERSANO, T ;
RAQUENO, J ;
GURBEL, P ;
COWFER, J ;
COHEN, M ;
CROSS, P ;
BITTL, J ;
EDDINGS, K ;
TAYLOR, M ;
DEROSA, K ;
HATTEL, L ;
COOPER, L ;
ESHELMAN, B ;
FINTEL, D ;
NIEMYSKI, P ;
KLEIN, L ;
KENNEDY, H ;
THORNTON, T ;
KEREIAKES, D ;
MARTIN, L ;
ANDERSON, L ;
HIGBY, N ;
ELLIS, S ;
BREZINA, K ;
GEORGE, B ;
CHAPEKIS, A ;
SMITH, D ;
ANWAR, A ;
GERBER, TL ;
PRITCHARD, GL ;
MYLER, R ;
SHAW, R ;
MURPHY, M ;
WARD, K ;
MADIGAN, NP ;
BLANKENSHIP, J ;
HALBERT, M ;
FLANAGAN, C ;
TANNENBAUM, M ;
POLICH, M ;
STEVENSON, C ;
TCHENG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961
[5]   Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction - Observations from the TIMI 14 trial [J].
de Lemos, JA ;
Antman, EM ;
Gibson, CM ;
McCabe, CH ;
Giugliano, RP ;
Murphy, SA ;
Coulter, SA ;
Anderson, K ;
Scherer, J ;
Frey, MJ ;
Van der Wieken, R ;
Van de Werf, F ;
Braunwald, E .
CIRCULATION, 2000, 101 (03) :239-243
[6]   EARLY PHASE ACUTE MYOCARDIAL INFARCT SIZE QUANTIFICATION - VALIDATION OF THE TRIPHENYL TETRAZOLIUM CHLORIDE TISSUE ENZYME STAINING TECHNIQUE [J].
FISHBEIN, MC ;
MEERBAUM, S ;
RIT, J ;
LANDO, U ;
KANMATSUSE, K ;
MERCIER, JC ;
CORDAY, E ;
GANZ, W .
AMERICAN HEART JOURNAL, 1981, 101 (05) :593-600
[7]  
Galiuto L, 2000, CIRCULATION, V102, P3111
[8]   CHANGES IN VASCULAR MORPHOLOGY ASSOCIATED WITH THE NO-REFLOW PHENOMENON IN ISCHEMIC MYOCARDIUM [J].
GAVIN, JB ;
THOMSON, RW ;
HUMPHREY, SM ;
HERDSON, PB .
VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1983, 399 (03) :325-332
[9]   Effect of Eptifibatide on coronary flow reserve following coronary stent implantation -: (An ESPRIT substudy) [J].
Gibson, CM ;
Cohen, DJ ;
Cohen, EA ;
Lui, HK ;
Murphy, SA ;
Marble, SJ ;
Kitt, M ;
Lorenz, T ;
Tcheng, JE .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (11) :1293-1295
[10]   Synergy between intracoronary stenting and abciximab improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction [J].
Giri, S ;
Mitchel, JF ;
Hirst, JA ;
McKay, RG ;
Azar, RR ;
Mennett, R ;
Waters, DD ;
Kiernan, FJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (03) :269-274